Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22752
Title: Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts.
Austin Authors: Yang, J C-H;Ramalingam, S S;Lee, C K;Kurata, T;Kim, D-W;John, Thomas ;Nogami, N;Ohe, Y;Rukazenkov, Y;Murphy, M;Jänne, P A
Affiliation: National Taiwan University and National Taiwan University Cancer Center, Taipei City, Taiwan
Austin Health, Heidelberg, Victoria, Australia
St. George Hospital, Sydney, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Emory School of Medicine, Winship Cancer Institute, Atlanta, GA, USA
Kansai Medical University Hospital, Osaka, Japan
Seoul National University Hospital, Seoul, Republic of Korea
National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
AstraZeneca, Cambridge, UK
Dana-Farber Cancer Institute, Boston, MA, USA
Issue Date: Apr-2019
Publication information: Annals of oncology : official journal of the European Society for Medical Oncology 2019; 30 Suppl 2: ii48
URI: http://ahro.austin.org.au/austinjspui/handle/1/22752
DOI: 10.1093/annonc/mdz063.020
PubMed URL: 32131238
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

8
checked on Dec 2, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.